Adalimumab in the treatment of pediatric patients with chronic noninfectious anterior uveitis

被引：3

作者：

Gunzinger, Jeanne ^{[1
]}

Moore, Phoebe ^{[1
]}

Athimalaipet, Ramanan ^{[2
,3
,4
]}

Dick, Andrew ^{[5
,6
,7
]}

机构：

[1] Bristol Eye Hosp, Dept Uveitis, Bristol, Avon, England

[2] Bristol Royal Hosp Children, Upper Maudlin St, Bristol BS2 8BJ, Avon, England

[3] Univ Bristol, Univ Hosp Bristol NHs Fdn Trust, Bristol, Avon, England

[4] Univ Bristol, Translat Hlth Sci, Bristol, Avon, England

[5] Bristol Eye Hosp, Inst Ophthalmol, Bristol, Avon, England

[6] Moorfields Eye Hosp, Biomed Res Ctr, Natl Inst Hlth Res, London, England

[7] UCL, London, England

来源：

EXPERT REVIEW OF OPHTHALMOLOGY | 2021年 / 16卷 / 04期

关键词：

Adalimumab; noninfectious pediatric uveitis; pediatric uveitis; anti-drug antibodies; uveitis treatment; adalimumab monitoring; JUVENILE IDIOPATHIC ARTHRITIS; LONG-TERM TREATMENT; RHEUMATOID-ARTHRITIS; TNF-ALPHA; DISEASE-ACTIVITY; BIOLOGICAL THERAPIES; REFRACTORY UVEITIS; EFFICACY; CHILDREN; TOCILIZUMAB;

D O I：

10.1080/17469899.2021.1935240

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Introduction: Adalimumab is established as an effective treatment for pediatric noninfectious uveitis refractory to methotrexate. However current use of the medication is empiric, according to fixed-dosing regimens and a significant proportion of patients will be nonresponsive or suboptimally responsive to adalimumab. Areas covered: There remains considerable scope to improve outcomes through tailoring treatment according to individual patient responsiveness. Monitoring of anti-drug antibodies and serum drug trough levels may assist in predicting which patients are likely to have a poor response to adalimumab and enable tailoring of regimens to individual patients. Expert opinion: We propose use of these biomarkers to individualize therapy in suboptimally responding patients, and present an algorithm of treatment escalation for pediatric noninfectious uveitis.

引用

页码：231 / 241

页数：11

共 99 条

[51] Favorable response to high-dose infliximab for refractory childhood uveitis [J].

Kahn, P ;

Weiss, M ;

Imundo, LF ;

Levy, DM .

OPHTHALMOLOGY, 2006, 113 (05) :860-864

[52] Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease [J].

Karmiris, Konstantinos ;

Paintaud, Gilles ;

Noman, Maja ;

Magdelaine-Beuzelin, Charlotte ;

Ferrante, Marc ;

Degenne, Danielle ;

Claes, Karolien ;

Coopman, Tamara ;

Van Schuerbeek, Nele ;

Van Assche, Gert ;

Vermeire, Severine ;

Rutgeerts, Paul .

GASTROENTEROLOGY, 2009, 137 (05) :1628-1640

[53] Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up [J].

Kneepkens, Eva L. ;

Wei, James Cheng-Chung ;

Nurmohamed, Michael T. ;

Yeo, Kai-Jieh ;

Chen, C. Y. ;

van der Horst-Bruinsma, Irene E. ;

van der Kleij, Desiree ;

Rispens, Theo ;

Wolbink, Gertjan ;

Krieckaert, Charlotte L. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) :396-401

[54] Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients [J].

Kotaniemi, K ;

Arkela-Kautiainen, M ;

Haapasaari, J ;

Leirisalo-Repo, M .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :871-874

[55] Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors [J].

Lerman, Melissa A. ;

Lewen, Michael D. ;

Kempen, John H. ;

Mills, Monte D. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 160 (01) :193-200

[56] Expert Panel Recommendations for the Use of Anti-Tumor Necrosis Factor Biologic Agents in Patients with Ocular Inflammatory Disorders [J].

Levy-Clarke, Grace ;

Jabs, Douglas A. ;

Read, Russell W. ;

Rosenbaum, James T. ;

Vitale, Albert ;

Van Gelder, Russell N. .

OPHTHALMOLOGY, 2014, 121 (03) :785-U215

[57] The Safety and Efficacy of Noncorticosteroid Triple Immunosuppressive Therapy in the Treatment of Refractory Chronic Noninfectious Uveitis in Childhood [J].

Little, Jessica A. ;

Sen, Ethan S. ;

Strike, Helen ;

Hinchcliffe, Annie ;

Guly, Catherine M. ;

Lee, Richard W. J. ;

Dick, Andrew D. ;

Ramanan, Athimalaipet V. .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (01) :136-139

[58] Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis [J].

Maccora, Ilaria ;

Fusco, Eleonora ;

Marrani, Edoardo ;

Ramanan, Athimalaipet, V ;

Simonini, Gabriele .

RHEUMATOLOGY, 2021, 60 (02) :568-587

[59] Low Percentage of Signal Regulatory Protein α/β+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients [J].

Magill, Laura ;

Adriani, Marsilio ;

Berthou, Veronique ;

Chen, Keguan ;

Gleizes, Aude ;

Hacein-Bey-Abina, Salima ;

Hincelin-Mery, Agnes ;

Mariette, Xavier ;

Pallardy, Marc ;

Spindeldreher, Sebastian ;

Szely, Natacha ;

Isenberg, David A. ;

Manson, Jessica J. ;

Jury, Elizabeth C. ;

Mauri, Claudia .

FRONTIERS IN IMMUNOLOGY, 2018, 9

[60] Adalimumab for juvenile idiopathic arthritis-associated uveitis [J].

Magli, Adriano ;

Forte, Raimondo ;

Navarro, Pasqualina ;

Russo, Giustina ;

Orlando, Francesca ;

Latanza, Loredana ;

Alessio, Maria .

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 251 (06) :1601-1606

← 1 2 3 4 5 6 7 8 9 10 →